Published in Int J Gynecol Cancer on February 06, 2004
A framework for a personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol (2015) 1.17
Diffusion-weighted magnetic resonance imaging evaluation of intra-abdominal sites of implants to predict likelihood of suboptimal cytoreductive surgery in patients with ovarian carcinoma. Eur Radiol (2013) 0.84
The Significance of Normal Pretreatment Levels of CA125 (<35 U/mL) in Epithelial Ovarian Carcinoma. Rambam Maimonides Med J (2015) 0.75
Preoperative Lymphocyte-Monocyte Ratio Is a Predictor of Suboptimal Cytoreduction in Stage III-IV Epithelial Ovarian Cancer. J Cancer (2016) 0.75
Advanced Primary Epithelial Ovarian and Peritoneal Carcinoma-Does Diagnostic Accuracy of Preoperative CT Scan for Detection of Peritoneal Metastatic Sites Reflect into Prediction of Suboptimal Debulking? A Prospective Study. Indian J Surg Oncol (2017) 0.75
A novel algorithm for the treatment strategy for advanced epithelial ovarian cancer: consecutive imaging, frailty assessment, and diagnostic laparoscopy. BMC Cancer (2017) 0.75
Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol (1989) 6.86
U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol (2002) 4.92
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol (2001) 4.45
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet (2001) 4.16
UK guidelines for the management of cutaneous melanoma. Br J Plast Surg (2002) 3.51
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol (2008) 3.44
Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther (2009) 2.73
A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOG (2008) 2.71
Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol (2000) 2.67
Infectious complications of subcutaneous interleukin-2 and interferon-alpha. Lancet (1992) 2.65
Natural history of stage IV epithelial ovarian cancer. J Clin Oncol (1999) 2.52
FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet (1999) 2.36
Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol (2012) 2.23
Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol (2010) 2.22
Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer. BMJ (1999) 2.21
Glove perforations during open surgery for gynaecological malignancies. BJOG (2008) 2.17
Modified staging system for extremity soft tissue sarcomas. Ann Surg Oncol (1999) 2.16
Management of metastatic melanoma during pregnancy. BMJ (1998) 2.10
Ovarian cancers related to minimal access surgery. Br J Obstet Gynaecol (1995) 2.02
Non-pharmacological intervention for breathlessness in lung cancer. Palliat Med (1996) 1.99
Psychosexual dysfunction in women with gynaecological cancer following radical pelvic surgery. Br J Obstet Gynaecol (1993) 1.93
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol (2006) 1.85
Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol (1996) 1.78
Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. The Systematic Review Steering Committee. Gynecol Oncol (1999) 1.60
Two-dimensional FDTD analysis of a pulsed microwave confocal system for breast cancer detection: fixed-focus and antenna-array sensors. IEEE Trans Biomed Eng (1998) 1.56
Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol (2001) 1.55
Chemotherapy for symptom control in recurrent squamous cell carcinoma of the head and neck. Ann Oncol (1997) 1.53
Are we using appropriate self-report questionnaires for detecting anxiety and depression in women with early breast cancer? Eur J Cancer (1999) 1.52
Prognostic index for extremity soft tissue sarcomas with isolated local recurrence. Ann Surg Oncol (2001) 1.52
A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Cancer (1995) 1.52
Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol (1985) 1.51
FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet (1999) 1.49
Indolent cutaneous prodrome of fatal HTLV-I infection. Lancet (1990) 1.48
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol (1987) 1.47
Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ (1991) 1.46
Outcome and predictive factors of local recurrence and distant metastases following primary surgical treatment of high-grade malignant phyllodes tumours of the breast. Eur J Surg Oncol (2001) 1.45
A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain. J Pain Symptom Manage (2001) 1.44
The significance of the concordance rate for type 1 (insulin-dependent) diabetes in identical twins. Diabetologia (1988) 1.41
The distribution of CA 125 in the reproductive tract of pregnant and non-pregnant women. Br J Obstet Gynaecol (1988) 1.40
Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol (2009) 1.40
Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat (1998) 1.39
Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. Eur J Cancer (1991) 1.39
Tamoxifen and the gynaecologist. Br J Obstet Gynaecol (1993) 1.38
Outpatient vulval biopsy--a note of caution. Br J Obstet Gynaecol (1995) 1.38
Tamoxifen and chemotherapy for refractory metastatic malignant melanoma. N Engl J Med (1993) 1.38
Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidone. Cancer Chemother Pharmacol (1988) 1.38
Fertility-sparing surgery for young women with early-stage cervical cancer. BJOG (2010) 1.38
A more rational basis for determining the activities used for radionuclide imaging? Eur J Nucl Med (1997) 1.37
Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol (2007) 1.29
Fatigue in advanced cancer: a prospective controlled cross-sectional study. Br J Cancer (1999) 1.28
A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol (2000) 1.27
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer (2013) 1.24
Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer (2000) 1.23
Molecular quantification and mapping of lymph-node micrometastases in cervical cancer. Lancet (2001) 1.21
Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer (1998) 1.19
Revised UK guidelines for the management of cutaneous melanoma 2010. J Plast Reconstr Aesthet Surg (2010) 1.16
Fractionation of mouse myeloma chromatin. Biochemistry (1973) 1.15
Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol (1997) 1.15
Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol (1995) 1.15
Imaging features of aggressive angiomyxoma. Clin Radiol (2003) 1.14
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer (2000) 1.13
Aggressive fibromatosis of the abdominal wall, limbs and limb girdles. Br J Surg (2004) 1.12
Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res (1987) 1.12
Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril (2000) 1.12
The psychosocial impact of bilateral prophylactic mastectomy: prospective study using questionnaires and semistructured interviews. BMJ (2001) 1.11
Primary non-Hodgkin's lymphoma of the ovaries: imaging findings. Br J Radiol (2007) 1.10
Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev (2000) 1.10
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer (2011) 1.10
Occult advanced cervical cancer. Br Med J (Clin Res Ed) (1985) 1.10
Steroid hormone regulation of ovalbumin and conalbumin gene transcription. A model based upon multiple regulatory sites and intermediary proteins. J Biol Chem (1981) 1.09
Diagnostic precision of CT in local staging of colon cancers: a meta-analysis. Clin Radiol (2010) 1.08
A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. Br J Cancer (2002) 1.08
Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases. Cancer (1999) 1.08
Mucinous ovarian cancer. Int J Gynecol Cancer (2007) 1.07
Lobular carcinoma in situ of the breast is not caused by constitutional mutations in the E-cadherin gene. Br J Cancer (2000) 1.07
Molecular profiling of cervical cancer progression. Br J Cancer (2007) 1.07
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin. Br J Cancer (2012) 1.06
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer (2007) 1.05
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. Br J Cancer (2012) 1.04
Psychosexual implications of gynaecological cancer. BMJ (1994) 1.04
A prospective study of 123I-labeled monoclonal antibody imaging in ovarian cancer. J Clin Oncol (1986) 1.03
A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer (1996) 1.03
Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer (1992) 1.03
A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer (2004) 1.01
Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol (1999) 1.01
Abdominal radical trachelectomy: a new surgical technique for the conservative management of cervical carcinoma. Br J Obstet Gynaecol (1997) 1.01
Prostaglandin E, pessaries for induction of labour. Lancet (1979) 1.01
Fatigue in patients with cancers of the breast or prostate undergoing radical radiotherapy. J Pain Symptom Manage (2001) 1.01
Role of MR imaging in the selection of patients with early cervical carcinoma for fertility-preserving surgery: initial experience. Radiology (1999) 1.00
The performance of magnetic resonance imaging in early cervical carcinoma: a long-term experience. Int J Gynecol Cancer (2007) 1.00
Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients. Ann Oncol (1995) 1.00